To read the full article sign up for free or sign in.
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.
BioWorld Deals and M&A Cancer Oncology Antibody Antibody-drug conjugate Monoclonal antibody Asia-Pacific China U.S.